Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fulvestrant.

Kwok Leung Cheung1, John F R Robertson

  • 1Professorial Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK. kl.cheung@nottingham.ac.uk

Expert Opinion on Investigational Drugs
|February 7, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Geriatric oncology in 2040: Exploring potential realities and challenges. A diverse perspective.

Journal of geriatric oncology·2026
Same author

Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Changing Practices in Axillary Surgery After Neoadjuvant Breast Cancer Therapy: Insights From the EUSOMA European Database.

Journal of surgical oncology·2025
Same author

Locally advanced breast cancers: the EUSOMA experience.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

East Midlands Breast Pain Pathway: An Evaluation of Community Breast Pain Clinics Across the East Midlands Cancer Alliance.

Journal of evaluation in clinical practice·2025
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Fulvestrant, an estrogen receptor (ER) downregulator, effectively treats advanced breast cancer in postmenopausal women. This pure anti-estrogen demonstrates comparable efficacy to anastrozole with minimal side effects.

Area of Science:

  • Endocrinology
  • Medical Oncology
  • Pharmacology

Background:

  • Fulvestrant is a novel estrogen receptor (ER) downregulator.
  • It acts as a pure anti-estrogen, blocking estrogen's effects without partial agonist activity.
  • Fulvestrant reduces ER, progesterone receptor, and cell proliferation markers.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of fulvestrant in treating postmenopausal advanced breast cancer.
  • To compare fulvestrant's efficacy with existing therapies like anastrozole.
  • To identify future research directions for fulvestrant.

Main Methods:

  • Large randomized clinical trials were conducted.
  • Efficacy was compared between fulvestrant and anastrozole.

Related Experiment Videos

  • Patient tolerability and side effects were assessed.

    • Main Results:

    • Fulvestrant demonstrated similar efficacy to anastrozole in treating postmenopausal advanced breast cancer.
    • The drug was well-tolerated with minimal systemic side effects.
    • Fulvestrant reduces key biomarkers associated with breast cancer growth.

    Conclusions:

    • Fulvestrant is an effective endocrine therapy for postmenopausal advanced breast cancer.
    • Its favorable tolerability profile makes it a viable treatment option.
    • Further research is needed for adjuvant/neoadjuvant settings and premenopausal women.